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Abstract
Background: Women who experience menopause are at higher cardiometabolic risk and often display adverse
changes in metabolic biomarkers compared with pre-menopausal women. It remains elusive whether the changes
in cardiometabolic biomarkers during the menopausal transition are due to ovarian aging or chronological aging.
Well-conducted longitudinal studies are required to determine this. The aim of this study was to explore the cross-
sectional and longitudinal associations of reproductive status, defined according to the 2012 Stages of Reproductive
Aging Workshop criteria, with 74 metabolic biomarkers, and establish whether any associations are independent of
age-related changes.
Methods: We determined cross-sectional associations of reproductive status with metabolic profiling in 3,312 UK
midlife women. In a subgroup of 1,492 women who had repeat assessments after 2.5 years, we assessed how the
change in reproductive status was associated with the changes in metabolic biomarkers. Metabolic profiles were
measured by high-throughput quantitative nuclear magnetic resonance metabolomics. In longitudinal analyses, we
compared the change in metabolic biomarkers for each reproductive-status category change to that of the reference
of being pre-menopausal at both time points. As all women aged by a similar amount during follow-up, these analyses
contribute to distinguishing age-related changes from those related to change in reproductive status.
Results: Consistent cross-sectional and longitudinal associations of menopause with a wide range of metabolic
biomarkers were observed, suggesting the transition to menopause induces multiple metabolic changes independent
of chronological aging. The metabolic changes included increased concentrations of very small very low-density
lipoproteins, intermediate-density lipoproteins, low-density lipoproteins (LDLs), remnant, and LDL cholesterol, and
reduced LDL particle size, all toward an atherogenic lipoprotein profile. Increased inflammation was suggested via an
inflammatory biomarker, glycoprotein acetyls, but not via C-reactive protein. Also, levels of glutamine and albumin
increased during the transition. Most of these metabolic changes seen at the time of becoming post-menopausal
remained or became slightly stronger during the post-menopausal years.
Conclusions: The transition to post-menopause has effects on multiple circulating metabolic biomarkers, over
and above the underlying age trajectory. The adverse changes in multiple apolipoprotein-B-containing
lipoprotein subclasses and increased inflammation may underlie women’s increased cardiometabolic risk in their
post-menopausal years.
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Background
Women in high-income countries live, on average,
between 35–40% of their life in the post-menopausal
state, with those in low- and middle-income countries
also increasingly spending a high proportion of their
lives post-menopausal [1]. Younger age at menopause is
related to increased risk of osteoporosis, cardiovascular
diseases (CVD), diabetes, and premature mortality, and
reduced risk of ovarian cancer and breast cancer [1–7].
Similarly, a number of disease markers, such as cardio-
vascular risk factors [e.g., levels of low-density lipopro-
tein (LDL) cholesterol and apolipoprotein B}, cognitive
function, and bone density, have been shown to have
more adverse levels in relation to future cardiometabolic
health in women who are post-menopausal compared
with those who are pre-menopausal [8–12]. Assessments
of biological aging, based on white cell DNA methyla-
tion, suggest that women experience an acceleration of
biological aging with the onset of the menopause [13].
The differences in the risk markers between post- and
pre-menopausal women could, thus, reflect the start of
biological aging and disease risk related to the change in
reproductive status and its associated sex hormone
changes. However, the transition to post-menopause is
often accompanied by the additional effects of chrono-
logical aging and midlife social adjustment [14] and in
cross-sectional studies it is impossible to distinguish the
effect of reproductive aging from the effect of chrono-
logical aging [11, 15].
The range of diseases related to age at menopause sug-
gest that it may have an impact on multiple metabolic
pathways. Prospective studies with repeat measurements
of comprehensive metabolic profiles, together with
accurate characterization of reproductive status, are
required to determine this. However, to date there have
been only a few prospective longitudinal studies and
these have had small sample sizes or poorly defined
reproductive status, or primarily explored changes in
standard lipids (total cholesterol, high-density lipopro-
tein (HDL) cholesterol, LDL cholesterol, triglycerides),
glucose, and sometimes insulin [16–19].
To study the molecular changes in response to
menopausal transition and its effects independent
from chronological aging, the present study investi-
gated the cross-sectional and longitudinal associations
of reproductive status, defined according to the 2012
Stages of Reproductive Aging Workshop (STRAW)
criteria [20], with 74 circulating metabolic measures.
These measures were primarily profiled by a high-
throughput nuclear magnetic resonance (NMR) meta-
bolomics platform [21–23], covering a wide range of
metabolic pathways including lipoprotein lipids, fatty
acids, amino acids, ketone bodies, and glycemic traits,
which are highly relevant to cardiometabolic risk.
Methods
Data from the Avon Longitudinal Study of Parents and
Children (ALSPAC) were used. Full details of the
recruitment, follow-up, and data collection for these
women have been reported previously and are available
on the study website (http://www.alspac.bris.ac.uk) [24,
25]. ALSPAC is a prospective population-based preg-
nancy cohort study that recruited 14,541 pregnancies to
women resident in the south west of England between 1
April 1991 and 31 December 1992. Among them, 13,761
individual women delivered at least one live birth and
their children have been the main focus of a detailed
follow-up since then. Approximately 18 years after their
original pregnancy, a detailed assessment of the mothers
was completed [25], and the current study is based on
the 3,312 mothers who attended a clinic assessment
between December 2008 and June 2011 [median age
(interquartile range): 48 (45, 51)] and a subgroup of
those women (N = 1,492) who attend a second follow-up
assessment approximately 2.5 years later [median age
(interquartile range): 51 (48, 54)]. Figure 1a illustrates
the flow of women into the eligible and analysis groups.
The baseline characteristics of the participating women
are shown in Table 1.
Assessment of reproductive status (exposure)
At both clinic assessments, women were asked a range
of questions regarding their menstrual cycle, including
its frequency and regularity and date of last menstrual
period, which enabled them to be categorized according
to the STRAW criteria [20]. There are ten STRAW
stages, which are grouped into three larger groups: (i)
reproductive (referred to as pre-menopause in this
paper), which includes categories −5 (beginning at
menarche and characterized by variable to regular men-
strual cycles), −4 (regular), −3b (regular) and −3a (start
of subtle changes in cycle length); (ii) menopausal transi-
tion, which includes categories −2 (variable length of
cycle) and −1 (categorized by episodes of amenorrhea of
≥60 days); (iii) post-menopause, which begins at the last
menstrual period and includes +1a (up to the first 2 years
since the last menstrual period), +1b (>2 to ≤3 years),
+1c (>3 to ≤6 years), and 2 (>6 years). To increase statis-
tical power and to reflect the precision with which the
women in our study felt they could describe their men-
strual cycle length and its change over time, in all ana-
lyses we combined women in all four pre-menopausal
categories (i.e. −5 to −3) into one pre-menopausal cat-
egory and combined those in the two menopausal transi-
tion categories (−2 and −1) into one menopausal
transition category (Fig. 1b). Women were also asked
about any previous hysterectomy, oophorectomy, endo-
metrial ablation, or radio- or chemotherapy related to
reproductive organs (together defined as surgical
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menopause), and about the use of hormone replacement
and contraception. To assess naturally occurring
changes across reproductive categories, we excluded a
priori those women who had experienced a surgical
menopause and those using hormone replacement or
hormonal contraception at baseline (for both analyses)
and also at follow-up (for longitudinal analyses) (Fig. 1a).
The remaining women, who had completed information
on STRAW data and metabolic profiles, were then clas-
sified into one of the six mutually exclusive
reproductive-status groups based on the STRAW criteria
(Fig. 1b, top row). None of the women were pregnant at
baseline or follow-up.
Assessment of metabolic profiling, anthropometry, and
blood pressure (outcomes)
At both assessments, blood samples were taken after an
overnight fast for those examined in the morning and a
minimum 6 hours for those seen after 14.00. Blood sam-
ples were immediately spun and frozen at −80 °C and all
assays completed for this study were undertaken within
3 years of storage and with no previous freeze/thaw
a
b
Fig. 1 Participant flow and study design. a Participant flow into eligible and analysis groups. b Study design and reproductive status defined by
STRAW criteria. HRT hormone replacement therapy, MT menopausal transition, PostM post-menopausal, PreM pre-menopausal
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cycles. A high-throughput NMR metabolomics platform
was used to quantify 73 lipid and metabolite measures
from stored EDTA plasma samples. The platform applies
a single experimental setup, which allows for the simul-
taneous quantification of routine lipids, 14 lipoprotein
subclasses and individual lipids transported by these par-
ticles, multiple fatty acids, glucose, various glycolysis
precursors, ketone bodies, and amino acids in absolute
concentration units. Details of this platform have been
published previously [21, 22], and it has been widely
applied in genetic and observational epidemiological
studies [23, 26–34]. Highly sensitive C-reactive protein
(CRP) was measured by an automated particle-enhanced
immunoturbidimetric assay (Roche UK). Together, these
74 metabolic measures are defined as the primary out-
comes and constitute the circulating metabolic profile.
In addition, we also analyzed the associations of repro-
ductive status with anthropometric measures and blood
pressure. Weight and height [used to calculate the body
mass index (BMI)] were measured in light clothing and
unshod. Weight was measured to the nearest 0.1 kg
using Tanita scales; height was measured to the nearest
0.1 cm using a Harpenden stadiometer. A Lunar Prodigy
dual-energy X-ray absorptiometry scan was used to
measure total body fat, trunk fat, and total body lean
mass. Seated blood pressure was measured with the
woman at rest, her arm supported, and the correct cuff
size (after measurement of arm circumference), using an
Omron M6 upper arm monitor. Two measurements
were taken and their mean used.
Assessment of potential confounders
Age was recorded at each assessment. Educational
attainment and ethnicity, which were considered poten-
tial confounders [17], were obtained by a questionnaire
when the women were originally recruited [25]. The use
of lipid-lowering medication, which affects lipid concen-
trations [28], was assessed by a questionnaire. Fat mass,
which affects the systemic metabolic profile [33], was
also considered as a potential confounder.
Statistical analyses
The metabolic measures were scaled to standard devi-
ation (SD) units (by subtracting the mean and divid-
ing by the standard deviation of all women included
in the baseline analysis). This scaling allows easy
comparison of multiple metabolic measures with dif-
ferent units or with large differences in their concen-
tration distributions.
In cross-sectional analyses, the heat map of metabolic
profile across the age groups was compared to the heat
map of metabolic profile across the reproductive-status
groups. Baseline women were categorized into different
age groups, largely defined in 1-year age categories (at
the extremes of the age range, the groups were collapsed
because of small numbers: 34 to 38 years and 59 to
63 years). Similarly, the same women were categorized
into six reproductive-status groups according to the
STRAW criteria (Fig. 1b, top row). Heat map colors il-
lustrate the mean concentration of metabolic outcomes
in each of these groups. Then, linear regression models
were used to quantify the differences in the metabolic
concentrations across the reproductive-status groups,
using pre-menopausal women as the reference group.
To increase statistical power, all four post-menopausal
groups were pooled together as a single post-
menopausal group (Fig. 1b, middle row).
In longitudinal analyses, a subgroup of women, who
had repeated exposure and outcome measures 2.5 years
later, were categorized into six groups based on their
baseline and follow-up reproductive status (Fig. 1b, bot-
tom row). Firstly, the mean difference between baseline
Table 1 Baseline characteristics for ALSPAC mothers
Characteristics Pre-menopausal (N = 2031) Menopausal transition (N = 620) Post-menopausal (N = 661)
Age (years) 46 [44–48] 50 [48–52] 54 [51–56]
Body mass index (kg/m2) 25 [23–29] 25 [22–29] 25 [22–29]
Height (cm) 164 [160–168] 164 [160–168] 163 [160–167]
Fat mass (kg) 25 [19–32] 24 [18–32] 25 [19–32]
Lean mass (kg) 41 [38–44] 41 [38–44] 40 [37–43]
Trunk fat mass (kg) 13 [9–18] 12 [9–17] 13 [9–17]
Systolic blood pressure (mmHg) 115 [109–124] 116 [109–125] 117 [110–127]
Diastolic blood pressure (mmHg) 70 [66–76] 71 [66–77] 72 [66–78]
Educated to university level n/N (%)a 301/1887 (16) 149/574 (26) 159/611 (26)
White European n/N (%)a 1835/1881 (98) 563/573 (98) 588/607 (97)
Lipid-lowering medication n/N (%) 29/2031 (1) 9/620 (1) 13/661 (2)
Values are presented as median [interquartile range] unless otherwise stated
an/N, number with the characteristic divided by the total number in the group with no missing data on that variable
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and follow-up for each outcome in all six categories was
calculated. Then, linear regression models were used to
estimate the differences in mean differences between five
change categories compared with those who were pre-
menopausal at both baseline and 2.5 years follow-up
(the reference group that primarily reflects age-related
changes). To increase statistical power, these longitu-
dinal metabolic changes associated with reproductive-
stage changes were obtained by meta-analyzing results
from the four groups of women (those changing from
pre-menopausal to the menopausal transition, meno-
pausal transition to 2.5 years later still in menopausal
transition, menopausal transition to post-menopause,
and pre- to post-menopause). Under the assumption
that changing from one reproductive-status category to
another is not associated with other changes that affect
outcomes (beyond the confounders that we adjust for),
this difference in differences is a valid means of testing
causal effects with longitudinal observational data [35].
As the metabolic changes in the reference groups esti-
mate the metabolic changes primarily due to 2.5 years of
chronological aging, the results for the difference in dif-
ferences can be interpreted as the extent to which the
longitudinal changes deviate from the underlying age
trajectory. For example, null associations illustrate that
the metabolic changes that occurred during the follow-
up were likely to be due only to an age-related change
(and little or no impact from changing reproductive
status), while pronounced associations demonstrate that
the reproductive-status changes were over and above the
age effect.
Due to the correlated nature of the metabolic bio-
markers, over 95% of the variation in the 74 metabolic
biomarkers was explained by 19 principal components.
Therefore, multiple testing correction, accounting for 19
independent tests using the Bonferroni method, resulted
in P < 0.002 (0.05/19) being denoted as statistically sig-
nificant [32, 34]. All analyses were undertaken in the
statistical software package R (version 3.4.0).
Additional analyses
In the main analyses, the cross-sectional and longitudinal
associations (linear regression models) were adjusted for
baseline age. In additional analyses, the cross-sectional
analyses were further adjusted for education, ethnicity,
lipid-lowering medication, fat mass, and height, and the
longitudinal analyses were additionally adjusted for base-
line education, ethnicity, and 2.5-year change in lipid-
lowering medication, fat mass, and height. Cross-sectional
and longitudinal analyses with anthropometric and blood
pressure outcomes were also undertaken. While our focus
here is on metabolic profiles, these analyses allowed com-
parisons with previous studies on the association between
reproductive status and established CVD risk factors.
Lastly, as both natural menopause and surgical meno-
pause indicate the decline of ovarian function, we exam-
ined, in those women who had been previously excluded,
the cross-sectional and longitudinal associations between
surgical menopause and metabolic profiles to explore
whether surgical menopause had a similar association pat-
tern to those seen for natural menopause.
Results
Of the 3,782 eligible women attending the baseline
assessment (i.e., after a priori exclusions) 3,312 (88%)
had complete data on reproductive status and systemic
metabolic measures. Equivalent numbers for the follow-
up assessment were 1,978 and 1,778 (90%) (Fig. 1a). A
total of 1,508 women had complete data at both time
points. The 3,312 women with complete baseline data
were included in cross-sectional analyses. The 1,492
women with complete baseline and follow-up data, and
who had a valid change in reproductive status over time
(16 women had a menopause status change that was not
plausible, e.g., appearing to change from post-
menopause to the menopause transition), were included
in longitudinal analyses. Broadly similar baseline charac-
teristics were observed for those women included in the
analyses, women excluded a priori, and those excluded
because of missing data (Additional file 1: Table S1).
Metabolic heat map of chronological aging and
menopause
Figure 2 (top panel) shows mean metabolic concentrations
for women aged from the late 30s to the early 60s. Con-
centration of multiple lipoprotein particles, including
intermediate-density lipoprotein (IDL) and LDL sub-
classes, and the individual lipids (triglycerides, cholesterol,
and phospholipids) transported by these particles,
increased with chronological age. The patterns of associa-
tions with these measures were similar, with the metabolic
concentrations on average being lowest during the late
30s to mid-40s, then slightly increased during the mid-40s
to early 50s, and became substantially higher from the
early 50s. Similar chronological aging patterns were
observed for apolipoprotein A1 and B, total cholesterol
and phospholipids, absolute fatty acid concentrations, the
ratio of omega-3 fatty acids and its subclass docosahexae-
noic acid (DHA), as well as multiple non-lipid measures
including glutamine, tyrosine, glucose, and citrate. Given
the average menopausal age is 51 for those of European
ancestry [36], it is plausible that the marked increases
around age 50 in these metabolic profiles were associated
with a reproductive-status change. Weaker increases
around and after the age of menopause were seen for very
low-density lipoprotein (VLDL) and HDL subclasses
(except for very small VLDL), the individual lipids in these
particles, and total triglycerides. LDL particle sizes became
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smaller with increasing age. Over and above the pattern
observed around the menopausal age, we also observed an
increase and then decrease in most VLDL subclasses, total
and VLDL triglycerides, all branch-chain amino acids (and
some of the other amino acids), lactate, pyruvate, albumin,
glycoprotein acetyls, and CRP roughly around ages 39 to
43. The biological reasons or confounding factors, which
could explain the increase in these metabolic measures
between these ages, are, however, unclear and we have
insufficient data on women in their earlier 30s to describe
fully the nature of these changes.
Figure 2 (bottom panel) illustrates the mean metabolic
concentrations across the reproductive groups. Multiple
metabolic concentrations were substantially greater in
post-menopausal compared with pre-menopausal
women, with a similar pattern to that seen for the
marked increase in metabolites at early 50s. Given that
the reproductive groups are based on individual men-
strual cycle patterns and each group has within it a large
variation in age (and overlap across categories), the simi-
lar metabolic patterns suggest that the metabolic aberra-
tions are associated with a change in reproductive status
over and above chronological aging.
Cross-sectional associations of reproductive status
Figure 3 (top panel) shows the cross-sectional age-
adjusted associations of reproductive status with 74
metabolic measures. In age-adjusted analyses, women
who were post-menopausal, compared with those who
were pre-menopausal, had higher concentrations of
multiple lipoprotein lipids, particularly the IDL and
LDL-related measures, and increased concentrations of
fatty acids and several non-lipid measures. In contrast,
there were only minor metabolic differences between
Fig. 2 Heat map of metabolic concentrations across age groups (top panel) and across reproductive categories (bottom panel). Top panel: age
groups are largely in 1-year age categories (at the extremes of age range, groups were collapsed because of small numbers: 34 to 38 years and
59 to 63 years). For each metabolic measure, mean metabolite concentrations across each age group are displayed in colors. The horizontal black
line marks the typical age of natural menopause in Europe. Bottom panel: reproductive categories are defined according to the STRAW criteria.
For each metabolic measure, mean metabolite concentrations across each menopausal category are displayed in colors. The age range of each
reproductive category is shown on the y-axis. As the metabolic measures were scaled to SD units, both analyses (aging and menopause) thus
used the population mean of all women at baseline as the reference value, marked as white boxes in the plots. The metabolic measures in both
panels are plotted in the same order. C cholesterol, DHA docosahexaenoic acid, FA fatty acids, HDL high-density lipoprotein, IDL intermediate-
density lipoprotein, MUFA monounsaturated fatty acids, PL phospholipids, PUFA polyunsaturated fatty acids, TG triglycerides, VLDL very
low-density lipoprotein
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women in the menopausal transition and those who
were pre-menopausal.
Longitudinal changes in response to reproductive-status
change
Figure 3 (bottom panel) shows the longitudinal differ-
ences in mean differences for each reproductive-status
change category compared with the reference category
of being pre-menopausal at both time points, reflecting
the amount by which outcomes changed over the
follow-up period in response to a change in the repro-
ductive status. Within each category of reproductive-
status change, including the reference category of
women who remained pre-menopausal at both time
points, metabolite concentrations changed as all women
aged 2.5 years during the follow-up (Additional file 1:
Figure S1). In comparison with those women who were
pre-menopausal at both time points, greater increases in
IDL- and LDL-related measures, a larger decrease in
LDL particle size, and greater changes in multiple fatty
acid and non-lipid measures were consistently observed
for the four groups of women who changed from pre-
menopausal to the menopausal transition, from the
menopausal transition to 2.5 years of greater exposure
to the menopausal transition, from the menopausal tran-
sition to post-menopausal and from pre- to post-
menopausal. These results suggest metabolic changes,
over and above the underlying age trajectory, occurring
during the transition period from pre- to post-
menopause. By contrast, the metabolic changes for those
women who were post-menopausal at both time points
were less notably different to those who were pre-
menopausal at both time points.
Summary of cross-sectional and longitudinal associations
of change in reproductive status
Figure 4 and Additional file 1: Table S2 summarize and
compare the cross-sectional and longitudinal associations
of reproductive status and its change with metabolic traits.
The cross-sectional results are differences in mean con-
centrations comparing post- to pre-menopausal women.
The longitudinal association results were meta-analyzed
across four groups of women (those changing from pre-
menopausal to the menopausal transition, the menopausal
transition to 2.5 years later still in the menopausal transi-
tion, the menopausal transition to post-menopause, and
pre- to post-menopause) compared with those who were
pre-menopausal at both time points. The fixed-effect
meta-analysis was done to increase statistical power, given
that these four groups displayed broadly similar metabolic
association patterns (Fig. 3 lower panel) and that all of
them represent, at least partly, the transition process from
pre- to post-menopause. A meta-analysis was undertaken,
as it would not have been possible to combine these
women into one single change group given they changed
through different categories.
Longitudinal associations of menopause were broadly
similar to the cross-sectional associations (Fig. 4). Con-
sistent associations were observed for increased concen-
trations of very small VLDL, IDL, and LDL particles, as
well as the cholesterol and phospholipids transported in
these particles, whereas there was little robust evidence
from cross-sectional or longitudinal analyses in support
Fig. 3 Cross-sectional (top panel) and longitudinal (bottom panel) associations of reproductive categories with 74 metabolic measures. Top panel: In
the cross-sectional analysis, women were categorized into pre-menopausal, menopausal transition, and post-menopausal groups. Using pre-
menopausal women as the reference group, the colors define the SD differences in each metabolite concentration between the other two groups
and the reference group (Fig. 1b). Bottom panel: In the longitudinal analysis, women were categorized into six groups based on their baseline and
follow-up reproductive status. Using those women who were pre-menopausal at both time points as the reference group, the colors illustrate the SD
differences in the concentration change during the follow-up between the other five groups and the reference group (Fig. 1b). Cross-sectional and
longitudinal associations were adjusted for baseline age. The metabolites are plotted in the same order as in Fig. 2. C cholesterol, DHA
docosahexaenoic acid, FA fatty acids, HDL high-density lipoprotein, IDL intermediate-density lipoprotein, MUFA monounsaturated fatty acids, PL
phospholipids, PUFA polyunsaturated fatty acids, SD standard deviation, TG triglycerides, VLDL very low-density lipoprotein
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of the associations with triglycerides. Large increases in
total cholesterol, remnant cholesterol, total phospho-
lipids, apolipoprotein B, and apolipoprotein A-1 were
also observed. However, there were only weak associa-
tions with HDL-related measures. While LDL particle
size decreased as women changed from pre- to post-
menopause, weak changes were seen for VLDL and
HDL particle sizes. Total fatty acids, omega-6 fatty acids,
and the subclass of linoleic acid were increased, and the
ratio of saturated fatty acids relative to total fatty acids
decreased as women transitioned from pre- to post-
menopause. For the non-lipid measures, large increases
were observed for glutamine, histidine, valine, albumin,
and acetate as women became post-menopausal. Inter-
estingly, glycoprotein acetyls (an inflammatory marker)
increased with the transition from pre- to post-
menopause, whereas change in reproductive status was
not robustly associated with the other inflammatory
marker CRP in either longitudinal or cross-sectional
analyses (the 95% confidence interval included the null
in the longitudinal analyses). The magnitudes of change
in these metabolic concentrations as women became
post-menopausal were broadly similar (~0.2 SDs).
Additional analyses
Cross-sectional associations of reproductive status with
circulating metabolic measures remained largely
unchanged when further adjusted for ethnicity, educa-
tion, fat mass, height, and lipid-lowering medication
(Additional file 1: Figure S2). Longitudinal associations
also remained similar when adjusted for additional
potential confounders, including baseline ethnicity and
education and 2.5-year change in fat mass, height, and
lipid-lowering medication (Additional file 1: Figure S2).
Fig. 4 Cross-sectional (blue) and longitudinal (red) associations of natural menopause with 74 metabolic measures. The cross-sectional
associations are differences in mean metabolites comparing post-menopausal to pre-menopausal women. The longitudinal associations are the
differences in mean differences over time comparing four groups meta-analyzed together (pre-menopause to menopause transition, menopause
transition at both times, menopause transition to post-menopause, and pre-menopause to post-menopause) to pre-menopause at both times
(the reference group). The meta-analysis of the four groups, each of which at least partly represent the transition process from pre-menopausal to
post-menopausal, was used to increase statistical power. Cross-sectional and longitudinal associations were adjusted for baseline age. C
cholesterol, CI confidence interval, DHA docosahexaenoic acid, FA fatty acids, HDL high-density lipoprotein, IDL intermediate-density lipoprotein,
MUFA monounsaturated fatty acids, PL phospholipids, PUFA polyunsaturated fatty acids, SD standard deviation, TG triglycerides, VLDL very
low-density lipoprotein
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Additional analyses of reproductive status with anthro-
pometry and blood pressures were also conducted
(Additional file 1: Figure S3). In cross-sectional analyses,
height and lean mass were lower, and total and truncal
fat mass, and diastolic blood pressure higher in post-
compared to pre-menopausal women. However, with the
exception of the inverse association with lean mass,
these differences did not reach our multiple testing p-
value threshold and were not replicated in longitudinal
analyses. Further, there was no strong evidence for the
association of reproductive-status change with BMI,
waist circumference, or systolic blood pressure in either
cross-sectional or longitudinal analyses. Associations of
surgical menopause with multiple metabolic measures
were seen in cross-sectional analysis, whereas longitu-
dinal results were imprecisely estimated and difficult to
interpret reliably due to the small number of women
who underwent a surgical menopause during the follow-
up (Additional file 1: Figure S4).
Discussion
In this study of 3,312 midlife women, cross-sectional
and longitudinal analyses were used to determine the
relation of reproductive status with comprehensive
metabolic profiles. Cross-sectional analyses showed that
being post-menopausal was associated with a wide range
of circulating metabolic measures, including multiple
established and emerging biomarkers for type 2 diabetes,
CVD, and all-cause mortality [26, 27, 37]. The difference
in mean differences in the longitudinal analyses dis-
played broadly consistent association patterns with the
cross-sectional analysis, suggesting the observed meta-
bolic aberrations were due to the effect of reproductive-
status change, over and above age-related changes.
These metabolic changes were primarily toward an
atherogenic lipid profile, with increased concentrations
of small VLDL, IDL, and LDL subclasses, higher levels
of all cholesterol measures except HDL cholesterol,
increased apolipoprotein-B, and decreased LDL particle
size. We also found that becoming post-menopausal
resulted in a decreased proportion of saturated fatty
acids, and higher concentrations of glutamine, valine,
albumin, acetate, and glycoprotein acetyls. The majority
of these metabolic changes appear to persist, or possibly
increase slightly, over time after becoming post-
menopausal.
One previous study examined cross-sectional associa-
tions of age with similar metabolic profiles to those
assessed here and showed that around the average age at
menopause for European women, the metabolic profiles
changed more so in women than men [8], with patterns
that are broadly consistent with our detailed
characterization of reproductive status and longitudinal
analyses. The Study of Women’s Health Across the
Nation (SWAN) is the previous largest study (N = 1,054)
to examine prospective associations of reproductive-
status change with changes in established risk factors
[17]. Consistent with our study, they found longitudinal
increases in total cholesterol, LDL cholesterol, and
apolipoprotein-B on becoming post-menopausal that
were independent of chronological aging. As in our
study, SWAN also found that changes in BMI, blood
pressure, triglycerides, HDL cholesterol, and CRP in
women’s midlife were small and/or largely expected to
be related to age, rather than a change in reproductive
status. Although there is little evidence supporting the
change in CRP in both SWAN and our longitudinal ana-
lysis, our results suggested that the change from pre- to
post-menopause increases the concentration of glyco-
protein acetyls, a biomarker for low-grade chronic in-
flammation, which has been shown to be positively
associated with diabetes, CVD, and premature mortality
[26, 38–41]. Thus, becoming post-menopausal may re-
sult in increased low-grade inflammation over and above
age effects. The overall consistent findings between our
study and the SWAN study (which used a multilevel
model analytical approach with a greater number of re-
peat measures) for the established risk markers also sug-
gest that the difference in mean differences approach
taken here is a valid way to assess the metabolic conse-
quences of change in reproductive status that is inde-
pendent of chronological aging.
Besides the established lipid and inflammatory
markers, our results provide longitudinal evidence for a
potential impact of becoming post-menopausal on lipo-
protein particles, fatty acids, amino acids, and other
metabolites. As women changed from pre- to post-
menopause, the atherogenic lipoprotein particles, includ-
ing the remnant (small VLDL + IDL) and LDL particle
concentrations, increased, while LDL particle size
decreased. These changes are likely to predispose post-
menopausal women toward higher CVD risk. Previous
studies have reported that branched-chain and aromatic
amino acids are predictive of type 2 diabetes, and that
their circulating levels increase in response to weight
gain and increases in insulin resistance [33, 42]. Transi-
tion to post-menopause had only a weak effect on these
amino acids, except for valine. These findings suggest
that the adverse metabolic changes observed here are
unlikely to be entirely mediated through weight gain or
increased insulin resistance during the transition period,
a finding consistent with our observation of little robust
evidence for a relation between a change in reproductive
status and a change in adiposity measurements, or a
change in the longitudinal effects on metabolic traits
with adjustment for both baseline and follow-up fat
mass and glucose. Interestingly, the transition to post-
menopause was associated with a decreased proportion
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of saturated fatty acids and increased concentration of
glutamine and albumin, all of which are associated with
lower cardiometabolic risk [26, 37, 43]. However, the
casual role of these emerging biomarkers for disease
risks remains unclear.
Menopause is associated with a decrease in estradiol,
beginning during the transition phase (~2 years before a
woman’s final menstrual period), with levels plateauing
at a low value by ~2 years post-menopause, and a mirror
pattern of increasing follicle stimulating hormone levels
over the same period [44]. The metabolic changes
observed here may, thus, reflect sex and gonadotropin
hormonal changes relating to the menopausal transition.
Previous studies have shown exogenous estrogen alone,
or in combination with progestogens [as hormone
replacement therapy (HRT) or combined hormonal
contraception], is associated with a variation in lipid levels
[30, 45]. Of relevance to our findings, post-menopausal
women using HRT were found to have lower LDL choles-
terol in comparison with those not using HRT [45]. How-
ever, these associations with exogenous hormones may
not be causal, and it remains unclear to what extent HRT
is associated with levels of non-lipid biomarkers, e.g. fatty
acids and amino acids. Several studies have recently found
exogenous hormones [30] and also reproductive-status
change, including pregnancy [31] and menopause (as
studied here) to be associated with changes in a wide
range of circulating metabolites. Further research to
understand the relationship between circulating levels of
reproductive hormones at different stages of the life
course and changes in comprehensive metabolic profiles
would be important in giving us a better understanding of
the extent to which sex hormones influence metabolism
during different reproductive stages of life.
The key strengths of this study are its detailed infor-
mation on reproductive status and comprehensive meta-
bolic profiles collected on two occasions prospectively in
large numbers. Our results are broadly supported by the
previous large-scale cross-sectional and longitudinal
studies of established risk factors [8, 17]. However, we
acknowledge that replication of the associations with the
emerging metabolic risk factors that we have assessed
here is important. Our results suggest that the majority
of the metabolic changes seen at the time of becoming
post-menopausal persist over time, and for some may
continue to change at a slow pace. However, the mean
age of women at baseline and follow-up were 48 and
51 years, respectively, and further repeat assessments in
these women would be valuable for verifying this, and to
determine how long such changes may continue. Col-
lapsing the STRAW reproductive-stage categories may
have obscured some differences in our cross-sectional
and longitudinal analyses. For example, in the longitu-
dinal analyses in the SWAN study, there was an increase
in conventional lipids between the early and late meno-
pausal transition period [16, 17]. The women in our
study were not able to describe confidently the change
in the length of their menstrual cycle with the precision
that would allow us to separate a variable length persist-
ing for at least 7 days with a consecutive difference in
length (early menopausal transition) from an interval of
amenorrhea of at least 60 days (late menopausal transi-
tion) and therefore, we had to collapse these two. These
two stages can also be distinguished by differences in
follicle stimulating hormone levels, but we currently do
not have these data. It is possible that the lack of differ-
ence between pre-menopausal women and those catego-
rized as in the menopausal transition for most lipids in
our cross-sectional analyses is because we cannot separ-
ate the early from the late menopausal transition. Fur-
thermore, the longitudinal differences for several
outcomes between those who remained in our category
of menopausal transition for 2.5 years and those
remaining pre-menopausal for this period may reflect
that the former included a high proportion who transi-
tioned from early to late menopausal transition status,
but we are unable to determine this.
These women are currently too young to have
experienced CVD events, osteoporotic fractures, or
cancer in sufficient numbers for us to be able to
examine the extent to which the menopause-related
changes that we have observed in metabolic profiles
relate to future disease outcomes. With a continued
follow-up of these women that would be possible.
The women in this study are largely of European ori-
gin and we cannot assume that our findings
generalize to other groups.
Conclusions
In conclusion, when women become post-menopausal,
they experience changes in relation to lipoprotein me-
tabolism, fatty acids, amino acids, and inflammation.
These metabolic changes are independent of age and
potentially underlie the relationship between menopause
and cardiometabolic diseases. A detailed understanding
of the molecular changes that occur during the meno-
pausal transition may lead to lifestyle or therapeutic
opportunities to diminish the adverse metabolic effects
on women during their post-menopausal life.
Additional file
Additional file 1: Supplementary tables and figures in support our
results and findings. (DOCX 187 kb)
Abbreviations
ALSPAC: Avon Longitudinal Study of Parents and Children; BMI: Body mass
index; CRP: Highly sensitive C-reactive protein; CVD: Cardiovascular diseases;
DHA: Docosahexaenoic acid; HDL: High-density lipoprotein; HRT: Hormone
Wang et al. BMC Medicine  (2018) 16:17 Page 10 of 12
replacement therapy; IDL: Intermediate-density lipoprotein; LDL: Low-density
lipoprotein; MUFA: Monounsaturated fatty acids; MT: Menopausal transition;
NMR: Nuclear magnetic resonance; PostM: Post-menopausal; PreM: Pre-
menopausal; SD: Standard deviation; STRAW: Stages of Reproductive Aging
Workshop; SWAN: The Study of Women’s Health Across the Nation;
VLDL: Very low-density lipoprotein
Acknowledgements
We are extremely grateful to all the families who took part in this study, the
midwives for their help in recruiting them, and the whole ALSPAC team,
which includes interviewers, computer and laboratory technicians, clerical
workers, research scientists, volunteers, managers, receptionists, and nurses.
Funding
This study is funded by the British Heart Foundation (SP/07/008/24066),
Wellcome (WT092830M; wellcome.ac.uk), and the UK Medical Research
Council (G1001357). ALSPAC receives core funding from the University of
Bristol, Wellcome, and the UK Medical Research Council (102215/2/13/2).
MAK receives funding from the Sigrid Juselius Foundation, Finland. DLSF,
MAK, and DAL work in a unit that receives funds from the University of
Bristol and the UK Medical Research Council (MC_UU_12013/1 and
MC_UU_12013/5). DAL is a senior investigator for the National Institute for
Health Research (NF-SI-0611–10196). The funders had no role in designing
the study, collecting or analyzing the data, or writing the paper. The views
expressed in this paper are those of the authors and not necessarily any
funding body.
Availability of data and materials
All ALSPAC data are available to scientists on request to the ALSPAC
executive via this website, which also provides full details and distributions
of the ALSPAC study variables: http://www.bristol.ac.uk/alspac/researchers/
access/. Consistent with other studies funded by UK funders, ALSPAC uses
a business model to offset the expense of preparing and supporting data
access. The ALSPAC data management plan (available from http://
www.bristol.ac.uk/media-library/sites/alspac/migrated/documents/alspac-
data-management-plan.pdf) describes in detail the policy regarding data
sharing, including the real costs for providing data. The system for accessing
data via the executive applies to all researchers including ALSPAC investigators
and scientists at the University of Bristol. The executive does not scrutinize the
proposed science by those wishing to access data, nor does it check for
scientific overlap with other data requests (all data requests are published
online at https://proposals.epi.bristol.ac.uk/). Requests are only refused if the
necessary data are not available or there are concerns that the proposed
research might bring the study into disrepute. Restrictions (including collapsing
categories) might be applied to some variables if cell numbers are small. An
independent scientific advisory board reviews the very small number of data
access requests that are declined. The study website contains details of
all the data that are available through a fully searchable data dictionary
(http://www.bristol.ac.uk/alspac/researchers/access/).
Authors’ contributions
All listed authors meet the requirements for authorship. QW, MAK, and DAL
designed this study and agreed the analysis plan. QW undertook the
analyses. DLSF provided support with data management. SNM and NS
supervised the laboratory assays for CRP. QW, MAK, and DAL wrote the
original draft of the study, with all other authors provideding comments.
DAL acts as guarantor. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Ethical approval was obtained from the ALSPAC Law and Ethics Committee
and the UK National Health Service Local Research Ethics Committee
(references 08/H0106/96 and 11/SW/0110). Women provided informed
written consent for their assessments and use of their blood samples.
Consent for publication
Not applicable.
Competing interests
SMN has received research support from Roche Diagnostics and Ferring
Pharmaceuticals for research unrelated to this paper. DAL has received
research support from Roche Diagnostics and Medtronic for research
unrelated to this paper. DAL was a member of the ALSPAC executive
from April 2007 to June 2017. All other authors declare they have no
competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Computational Medicine, Faculty of Medicine, University of Oulu and
Biocenter Oulu, Oulu, Finland. 2MRC Integrative Epidemiology Unit at the
University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, UK.
3Population Health Science, Bristol Medical School, University of Bristol,
Bristol, UK. 4School of Medicine, University of Glasgow, Glasgow, UK.
5Institute of Cardiovascular and Medical Sciences, University of Glasgow,
Glasgow, UK. 6NMR Metabolomics Laboratory, School of Pharmacy, University
of Eastern Finland, Kuopio, Finland. 7Systems Epidemiology, Baker Heart and
Diabetes Institute, Melbourne, VIC, Australia. 8Department of Epidemiology
and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences,
School of Public Health and Preventive Medicine, The Alfred Hospital,
Monash University, Melbourne, VIC, Australia.
Received: 29 September 2017 Accepted: 17 January 2018
References
1. Lobo RA. Menopause and aging. In: Barbiera RL, editor. Yen and Jaffe's
reproductive endocrinology, physiology, pathophysiology and clinical
management. 7th ed. Philadelphia: Elsevier Saunders; 2013. p. 308–39.
2. Ossewaarde ME, Bots ML, Verbeek ALM, Peeters PHM, van der Graaf Y,
Grobbee DE, et al. Age at menopause, cause-specific mortality and total life
expectancy. Epidemiology. 2005;16:556–62.
3. Atsma F, Bartelink M-LEL, Grobbee DE, van der Schouw YT. Postmenopausal
status and early menopause as independent risk factors for cardiovascular
disease: a meta-analysis. Menopause. 2006;13:265–79.
4. Gallagher JC. Effect of early menopause on bone mineral density and
fractures. Menopause. 2007;14:567–71.
5. Li S, Rosenberg L, Wise LA, Boggs DA, LaValley M, Palmer JR. Age at natural
menopause in relation to all-cause and cause-specific mortality in a follow-
up study of US black women. Maturitas. 2013;75:246–52.
6. Day FR, Ruth KS, Thompson DJ, Lunetta KL, Pervjakova N, Chasman DI, et al.
Large-scale genomic analyses link reproductive aging to hypothalamic
signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nat
Genet. 2015;47:1294–303.
7. Hartge P. Genetics of reproductive lifespan. Nat Genet. 2009;41:637–8.
8. Auro K, Joensuu A, Fischer K, Kettunen J, Salo P, Mattsson H, et al. A
metabolic view on menopause and ageing. Nat Commun. 2014;5:4708.
9. Finkelstein JS, Brockwell SE, Mehta V, Greendale GA, Sowers MR, Ettinger B,
et al. Bone mineral density changes during the menopause transition in a
multiethnic cohort of women. J Clin Endocrinol Metab. 2008;93:861–8.
10. Meyer PM, Powell LH, Wilson RS, Everson-Rose SA, Kravitz HM, Luborsky JL,
et al. A population-based longitudinal study of cognitive functioning in the
menopausal transition. Neurology. 2003;61:801–6.
11. Hardy R, Lawlor DA, Kuh D. A life course approach to cardiovascular aging.
Future Cardiol. 2015;11:101–13.
12. Lawlor DA, Hardy R. A life course approach to metabolic and vascular
function. In: Kuh D, Cooper R, Hardy R, Richards M, Ben-Shlomo Y, editors. A
life course approach to healthy ageing. Oxford: Oxford University Press; 2013.
13. Levine ME, Lu AT, Chen BH, Hernandez DG, Singleton AB, Ferrucci L, et al.
Menopause accelerates biological aging. Proc Natl Acad Sci. 2016;113:9327–32.
14. Nelson HD. Menopause. Lancet. 2008;371:760–70.
15. Bittner V. Menopause, age, and cardiovascular risk: a complex relationship. J
Am Coll Cardiol. 2009;54:2374–5.
16. Derby CA, Crawford SL, Pasternak RC, Sowers M, Sternfeld B, Matthews KA.
Lipid changes during the menopause transition in relation to age and
weight: The Study of Women's Health Across the Nation. Am J Epidemiol.
2009;169:1352–61.
17. Matthews KA, Crawford SL, Chae CU, Everson-Rose SA, Sowers MF, Sternfeld
B, et al. Are changes in cardiovascular disease risk factors in midlife women
due to chronological aging or to the menopausal transition? J Am Coll
Cardiol. 2009;54:2366–73.
Wang et al. BMC Medicine  (2018) 16:17 Page 11 of 12
18. Do KA, Green A, Guthrie JR, Dudley EC, Burger HG, Dennerstein L.
Longitudinal study of risk factors for coronary heart disease across the
menopausal transition. Am J Epidemiol. 2000;151:584–93.
19. El Khoudary SR, Hutchins PM, Matthews KA, Brooks MM, Orchard TJ, Ronsein
GE, et al. Cholesterol efflux capacity and subclasses of HDL particles in
healthy women transitioning through menopause. J Clin Endocrinol Metab.
2016;101:3419–28.
20. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al. Executive
summary of the stages of reproductive aging workshop + 10: addressing
the unfinished agenda of staging reproductive aging. J Clin Endocrinol
Metab. 2012;97:1159–68.
21. Soininen P, Kangas AJ, Würtz P, Tukiainen T, Tynkkynen T, Laatikainen R, et
al. High-throughput serum NMR metabonomics for cost-effective holistic
studies on systemic metabolism. Analyst. 2009;134:1781–5.
22. Soininen P, Kangas AJ, Würtz P, Suna T, Ala-Korpela M. Quantitative serum
nuclear magnetic resonance metabolomics in cardiovascular epidemiology
and genetics. Circ Cardiovasc Genet. 2015;8:192–206.
23. Würtz P, Kangas AJ, Soininen P, Lawlor DA, Davey Smith G, Ala-Korpela M.
Quantitative serum NMR metabolomics in large-scale epidemiology: a
primer on -omic technology. Am J Epidemiol. 2017;186:1084–96.
24. Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J, et al.
Cohort Profile: the ‘children of the 90s’ – the index offspring of the
Avon Longitudinal Study of Parents and Children. Int J Epidemiol. 2013;
42:111–27.
25. Fraser A, Macdonald-Wallis C, Tilling K, Boyd A, Golding J, Davey Smith G, et
al. Cohort profile: The Avon Longitudinal Study of Parents and Children:
ALSPAC mothers cohort. Int J Epidemiol. 2013;42:97–110.
26. Fischer K, Kettunen J, Würtz P, Haller T, Havulinna AS, Kangas AJ, et al.
Biomarker profiling by nuclear magnetic resonance spectroscopy for the
prediction of all-cause mortality: an observational study of 17,345 persons.
PLoS Med. 2014;11:e1001606.
27. Würtz P, Havulinna AS, Soininen P, Tynkkynen T, Prieto-Merino D,
Tillin T, et al. Metabolite profiling and cardiovascular event risk: a
prospective study of three population-based cohorts. Circulation.
2015;131:774–85.
28. Würtz P, Wang Q, Soininen P, Kangas AJ, Fatemifar G, Tynkkynen T, et al.
Metabolomic profiling of statin use and genetic inhibition of HMG-CoA
reductase. J Am Coll Cardiol. 2016;67:1200–10.
29. Kettunen J, Demirkan A, Würtz P, Draisma HHM, Haller T, Rawal R, et al.
Genome-wide study for circulating metabolites identifies 62 loci and reveals
novel systemic effects of LPA. Nat Commun. 2016;7:11122.
30. Wang Q, Würtz P, Auro K, Morin Papunen L, Kangas AJ, Soininen P, et al.
Effects of hormonal contraception on systemic metabolism: cross-sectional
and longitudinal evidence. Int J Epidemiol. 2016;45:1445–57.
31. Wang Q, Würtz P, Auro K, Mäkinen V-P, Kangas AJ, Soininen P, et al.
Metabolic profiling of pregnancy: cross-sectional and longitudinal evidence.
BMC Med. 2016;14:205.
32. Wang Q, Kangas AJ, Soininen P, Tiainen M, Tynkkynen T, Puukka K, et al. Sex
hormone-binding globulin associations with circulating lipids and
metabolites and the risk for type 2 diabetes: observational and causal effect
estimates. Int J Epidemiol. 2015;44:623–37.
33. Würtz P, Wang Q, Kangas AJ, Richmond RC, Skarp J, Tiainen M, et al.
Metabolic signatures of adiposity in young adults: mendelian randomization
analysis and effects of weight change. PLoS Med. 2014;11:e1001765.
34. Kujala UM, Mäkinen V-P, Heinonen I, Soininen P, Kangas AJ, Leskinen TH, et
al. Long-term leisure-time physical activity and serum metabolome.
Circulation. 2013;127:340–8.
35. Angrist JD, Pischke J-S. Differences in differences. In: Mostly harmless
econometrics: an empiricist's companion. Princeton: Princeton University
Press; 2008. p. 169–82.
36. Schoenaker DAJM, Jackson CA, Rowlands JV, Mishra GD. Socioeconomic
position, lifestyle factors and age at natural menopause: a systematic review
and meta-analyses of studies across six continents. Int J Epidemiol. 2014;43:
1542–62.
37. Guasch-Ferré M, Hruby A, Toledo E, Clish CB, Martínez-González MA, Salas-
Salvadó J, et al. Metabolomics in prediabetes and diabetes: a systematic
review and meta-analysis. Diabetes Care. 2016;39:833–46.
38. Ritchie SC, Würtz P, Nath AP, Abraham G, Havulinna AS, Fearnley LG, et al.
The biomarker GlycA is associated with chronic inflammation and predicts
long-term risk of severe infection. Cell Systems. 2015;1:293–301.
39. Akinkuolie AO, Pradhan AD, Buring JE, Ridker PM, Mora S. Novel protein
glycan side-chain biomarker and risk of incident type 2 diabetes mellitus.
Arterioscler Thromb Vasc Biol. 2015;35:1544–50.
40. Akinkuolie AO, Buring JE, Ridker PM, Mora S. A novel protein glycan
biomarker and future cardiovascular disease events. J Am Heart Assoc. 2014;
3:e001221.
41. Ala-Korpela M. Serum nuclear magnetic resonance spectroscopy: one more
step toward clinical utility. Clin Chem. 2015;61:681–3.
42. Würtz P, Soininen P, Kangas AJ, Rönnemaa T, Lehtimäki T, Kähönen M, et al.
Branched-chain and aromatic amino acids are predictors of insulin
resistance in young adults. Diabetes Care. 2013;36:648–55.
43. Chowdhury R, Warnakula S, Kunutsor S, Crowe F, Ward HA, Johnson L, et al.
Association of dietary, circulating, and supplement fatty acids with coronary
risk: a systematic review and meta-analysis. Ann Intern Med. 2014;160:398–406.
44. Randolph JF, Zheng H, Sowers MR, Crandall C, Crawford S, Gold EB, et al.
Change in follicle-stimulating hormone and estradiol across the
menopausal transition: effect of age at the final menstrual period. J Clin
Endocrinol Metab. 2011;96:746–54.
45. Godsland IF. Biology: risk factor modification by OCs and HRT lipids and
lipoproteins. Maturitas. 2004;47:299–303.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Wang et al. BMC Medicine  (2018) 16:17 Page 12 of 12
